N. Pluck
About
In The Last Decade
N. Pluck
11 papers receiving 2.4k citations
Hit Papers
Peers
Comparison fields: 5 of 64
- Epidemiology 2.4k
- Hepatology 2.3k
- Infectious Diseases 160
- Immunology 109
- Molecular Biology 37
Countries citing papers authored by N. Pluck
This map shows the geographic impact of N. Pluck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Pluck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Pluck more than expected).
Fields of papers citing papers by N. Pluck
This network shows the impact of papers produced by N. Pluck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Pluck. The network helps show where N. Pluck may publish in the future.
Co-authorship network of co-authors of N. Pluck
This figure shows the co-authorship network connecting the top 25 collaborators of N. Pluck. A scholar is included among the top collaborators of N. Pluck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Pluck. N. Pluck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | The IMPACT Study: Valganciclovir Prophylaxis for until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease. | 10 |
| 2 | 51 | |
| 3 | Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B breakdown → | 1143 |
| 4 | Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B breakdown → | 847 |
| 5 | 7 | |
| 6 | 376 | |
| 7 | 7 | |
| 8 | 6 | |
| 9 | 5 | |
| 10 | 44 | |
| 11 | 23 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.